PD-L1 inhibitors for the treatment of prostate cancer.

PD-L1 inhibitors for the treatment of prostate cancer.
Curr Drug Targets. 2020 Jun 09;:
Authors: Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A
Abstract
The carcinogenesis of prostate cancer (PCa) results from a complex series of events. Chronic inflammation and infections are crucial in this context. Infiltrating M2 type macrophages, as well as neutrophils and T lymphocytes, contribute to PCa development, progression and response to therapy. The preliminary findings on the efficacy of immunotherapy in patients with PCa were not encouraging. However, a series of studies investigating anti-PD-L1 agents such as Atezolizumab, Avelumab and Durvalumab used alone or in combination with other immunotherapies, chemotherapy or loco-regional approaches are in course in this tumor. In this review, we illustrate the role of immune cells and PD-L1 expression during PCa carcinogenesis and progression, with a focus on ongoing clinical trials on anti-PD-L1 agents in this context.
PMID: 32516098 [PubMed - as supplied by publisher]

Source: Current Drug Targets - June 8, 2020 Category: Drugs & Pharmacology Authors: Santoni M, Massari F, Cheng L, Cimadamore A, Scarpelli M, Montironi R, Lopez-Beltran A Tags: Curr Drug Targets Source Type: research